Literature DB >> 24263192

A case of penile squamous cell carcinoma treated with a combination of antiepidermal growth factor receptor antibody and chemotherapy.

Hai-Tao Men1, Hong-Feng Gou, Meng Qiu, Jian-Ping He, Ke Cheng, Ye Chen, Jun Ge, Ji-Yan Liu.   

Abstract

Our previous study showed that the features of epidermal growth factor receptor (EGFR)-RAS signaling in penile squamous cell carcinoma (SCC) suggested potential benefits of anti-EGFR monoclonal antibodies (mAbs) for penile SCC. Here, we report, for the first time, a combination of nimotuzumab (an EGFR mAb) with chemotherapy that resulted in a partial response in a 44-year-old patient with penile SCC, who developed bilateral inguinal node metastasis after primary partial penile amputation. The literature of case reports of anti-EGFR mAbs in penile SCC was also reviewed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24263192     DOI: 10.1097/CAD.0000000000000024

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  4 in total

1.  A phase 1 study of ABT-806 in subjects with advanced solid tumors.

Authors:  James M Cleary; David A Reardon; Nilofer Azad; Leena Gandhi; Geoffrey I Shapiro; Jorge Chaves; Michelle Pedersen; Peter Ansell; William Ames; Hao Xiong; Wijith Munasinghe; Matt Dudley; Edward B Reilly; Kyle Holen; Rod Humerickhouse
Journal:  Invest New Drugs       Date:  2015-04-17       Impact factor: 3.850

2.  Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab: A case report.

Authors:  Peng Song; Jing Yang; Xiaomei Li; Haili Huang; Xueguang Guo; Gang Zhou; Xian Xu; Yi Cai; Min Zhu; Peng Wang; Shu Zhao; Dong Zhang
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

Review 3.  Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors.

Authors:  Weijie Gu; Yao Zhu; Dingwei Ye
Journal:  Transl Androl Urol       Date:  2017-10

4.  Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact.

Authors:  Hellen Kuasne; Mateus C Barros-Filho; Ariane Busso-Lopes; Fábio A Marchi; Maisa Pinheiro; Juan J M Muñoz; Cristovam Scapulatempo-Neto; Eliney F Faria; Gustavo C Guimarães; Ademar Lopes; José C S Trindade-Filho; Maria Aparecida C Domingues; Sandra A Drigo; Silvia R Rogatto
Journal:  Oncotarget       Date:  2017-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.